Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis
- PMID: 34415962
- PMCID: PMC8378756
- DOI: 10.1371/journal.pone.0256429
Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic since its outbreak in Wuhan, China. It is an urgent task to prevent and treat COVID-19 effectively early. In China's experience combating the COVID-19 pandemic, Chinese herbal medicine (CHM) has played an indispensable role. A large number of epidemiological investigations have shown that mild to moderate COVID-19 accounts for the largest proportion of cases. It is of great importance to treat such COVID-19 cases, which can help control epidemic progression. Many trials have shown that CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 was superior to conventional therapy alone. This review was designed to evaluate the add-on effect of CHM in the treatment of mild to moderate COVID-19.
Methods: Eight electronic databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the Clinical Trials.gov website, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Database and China Biology Medicine (CBM) were searched from December 2019 to March 2021 without language restrictions. Two reviewers searched and selected studies, and extracted data according to inclusion and exclusion criteria independently. Cochrane Risk of Bias (ROB) tool was used to assess the methodological quality of the included RCTs. Review Manager 5.3.0 software was used for statistical analysis.
Results: Twelve eligible RCTs including 1393 participants were included in this meta-analysis. Our meta-analyses found that lung CT parameters [RR = 1.26, 95% CI (1.15, 1.38), P<0.00001] and the clinical cure rate [RR = 1.26, 95%CI (1.16, 1.38), P<0.00001] of CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 were better than those of conventional therapy. The rate of conversion to severe cases [RR = 0.48, 95%CI (0.32, 0.73), P = 0.0005], TCM symptom score of fever [MD = -0.62, 95%CI (-0.79, -0.45), P<0.00001], cough cases [RR = 1.43, 95%CI (1.16, 1.75), P = 0.0006], TCM symptom score of cough[MD = -1.07, 95%CI (-1.29, -0.85), P<0.00001], TCM symptom score of fatigue[MD = -0.66, 95%CI (-1.05, -0.28), P = 0.0007], and CRP[MD = -5.46, 95%CI (-8.19, -2.72), P<0.0001] of combination therapy was significantly lower than that of conventional therapy. The WBC count was significantly higher than that of conventional therapy[MD = 0.38, 95%CI (0.31, 0.44), P<0.00001]. Our meta-analysis results were robust through sensitivity analysis.
Conclusion: Chinese herbal medicine combined with conventional therapy may be effective and safe in the treatment of mild to moderate COVID-19. More high-quality RCTs are needed in the future.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g001.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g002.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g003.gif)
![Fig 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g004.gif)
![Fig 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g005.gif)
![Fig 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g006.gif)
![Fig 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8378756/bin/pone.0256429.g007.gif)
Similar articles
-
A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.Expert Rev Mol Med. 2022 Jan 6;24:e5. doi: 10.1017/erm.2021.35. Expert Rev Mol Med. 2022. PMID: 34986905 Free PMC article. Review.
-
Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: A systematic review and network meta-analysis.Medicine (Baltimore). 2021 Oct 8;100(40):e27372. doi: 10.1097/MD.0000000000027372. Medicine (Baltimore). 2021. PMID: 34622839 Free PMC article.
-
Add-On Effect of Honeysuckle in the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.Front Pharmacol. 2021 Sep 15;12:708636. doi: 10.3389/fphar.2021.708636. eCollection 2021. Front Pharmacol. 2021. PMID: 34603023 Free PMC article. Review.
-
Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.J Integr Med. 2020 Sep;18(5):385-394. doi: 10.1016/j.joim.2020.07.008. Epub 2020 Jul 31. J Integr Med. 2020. PMID: 32792254 Free PMC article.
-
Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.Pharmacol Res. 2020 Oct;160:105056. doi: 10.1016/j.phrs.2020.105056. Epub 2020 Jul 2. Pharmacol Res. 2020. PMID: 32622723 Free PMC article.
Cited by
-
Combination of Chinese herbal medicine and conventional western medicine for coronavirus disease 2019: a systematic review and meta-analysis.Front Med (Lausanne). 2023 Jul 17;10:1175827. doi: 10.3389/fmed.2023.1175827. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37529247 Free PMC article.
-
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.PLoS One. 2023 Mar 16;18(3):e0282688. doi: 10.1371/journal.pone.0282688. eCollection 2023. PLoS One. 2023. PMID: 36928877 Free PMC article. Clinical Trial.
-
Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update.Clin Complement Med Pharmacol. 2022 Mar;2(1):100021. doi: 10.1016/j.ccmp.2022.100021. Epub 2022 Feb 5. Clin Complement Med Pharmacol. 2022. PMID: 36620357 Free PMC article. Review.
-
Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review.Res Social Adm Pharm. 2023 Mar;19(3):343-355. doi: 10.1016/j.sapharm.2022.11.004. Epub 2022 Nov 13. Res Social Adm Pharm. 2023. PMID: 36402712 Free PMC article. Review.
-
Nutraceuticals and COVID-19: A mechanistic approach toward attenuating the disease complications.J Food Biochem. 2022 Dec;46(12):e14445. doi: 10.1111/jfbc.14445. Epub 2022 Oct 14. J Food Biochem. 2022. PMID: 36239436 Free PMC article. Review.
References
-
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard.2021 [EB/OL]. https://covid19.who.int/ (accessed Mar 26, 2021).
-
- Gao XM. Traditional Chinese Pharmacy (advanced series of traditional Chinese medicine) [M]. Beijing: People’s Health Publishing House, 2000.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous